464 filings
Page 12 of 24
6-K
qmlqabq xsdo
24 Jul 20
Current report (foreign)
6:30am
6-K
qjj 6lnzrjqw
8 Jul 20
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
6:11am
6-K
377v7j7i3 t6nw0
7 Jul 20
Notification of Dilution of Voting Rights
6:22am
6-K
j9pbyu4
29 Jun 20
Current report (foreign)
6:32am
6-K
3xws45s
26 Jun 20
Chi-Med to Announce 2020 Half-Year Financial Results
6:24am
6-K
g3bb04uv 95g
25 Jun 20
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
6:16am
6-K
aqnqu
18 Jun 20
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
6:18am
6-K
k8misz9p9esi2w60jf4
9 Jun 20
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
6:19am
6-K
df0tlh4
4 Jun 20
Current report (foreign)
6:21am
6-K
0qj2xpqlzfvdg08aosfq
1 Jun 20
Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
6:11am
6-K
de7vk6kt
29 May 20
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
8:13am
6-K
4vbd3lv
26 May 20
Current report (foreign)
6:16am
6-K
9ire76dzb
14 May 20
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
6:22am
6-K
2xurzenmnubv2h
11 May 20
Chi-Med to Attend Upcoming Investor Conferences
6:42am
20-F/A
mwrr0lp
29 Apr 20
Annual report (foreign) (amended)
7:47am
6-K
lkgvr
29 Apr 20
Current report (foreign)
6:58am
6-K
b8he4upd3o
27 Apr 20
Results of Annual General Meeting
9:23am
6-K
pe8rgsmw33c 1lf1g4d
22 Apr 20
Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
6:23am
6-K
iq0u4x5 8dcpnnf1
21 Apr 20
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
6:45am
6-K
hdjov2buh4egd13dd7
17 Apr 20
Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
6:23am